Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. InvestorsGlobeNewsWire · 5 days ago
XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?Zacks Investment Research · Oct 15, 2026
Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. InvestorsGlobeNewsWire · Oct 7, 2026
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Oct 2, 2026
Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of DirectorsNewsfile Corp · Sep 29, 2026
Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability ReviewMarketBeat · Sep 27, 2026Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$1.14 | -$1.11 | Beat |
| May 7, 2026 | -$1.17 | -$1.17 | Beat |
| Feb 26, 2026 | -$1.20 | -$1.31 | Miss |
| Nov 3, 2025 | -$1.16 | -$1.15 | Beat |
| Aug 11, 2025 | -$1.03 | -$1.07 | Miss |
| May 12, 2025 | -$0.94 | -$0.83 | Beat |